Mycamine will initially be available in the UK and across the European market shortly after this.
David Denning of the University of Manchester said: “The approval of micafungin is very good news for patients with life-threatening fungal infections in Europe. The company has conducted a number of large, high quality clinical studies in Candida infections with impressive results. Particularly welcome are the indications for fungal infections in children and babies, often a neglected group in the early drug approval process.”